UNSPSC 51162401: Dextromethorphan/guaifenesin/phenylephrine

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE513. This VA Drug Class (RE513) classifies this compound as belonging to the group DECONGESTANT/ANTITUSSIVE/EXPECTORANT.

UNSPSC 51162401 Dextromethorphan/guaifenesin/phenylephrine is a Commodity code that encompasses pharmaceutical products, though recent state and local procurement activity under this code shows limited direct alignment with the specific active ingredient combination the code nominally describes. Instead, the opportunities tagged to this code reflect broader pharmaceutical and over-the-counter product procurement by state and local health agencies, including naloxone, safe drug deactivation systems, and multi-source generic pharmaceuticals distributed through established wholesaler networks. State and local issuing bodies pursuing contracts under this code include county health departments and state cooperative purchasing alliances. Seminole County, Florida and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represent the primary recent buyers. These entities procure pharmaceuticals and related health products for community health initiatives, emergency response, and broader state and local facility distribution networks, with contracts typically requiring compliance with cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, FDA requirements, and E-Verify authorization.

Recent procurement activity under this code centers in Florida and Minnesota. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2026, and quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. MMCAP released RFP S1070000015802 on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed to state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026, and awarded vendors to be provided to authorized wholesalers (AmerisourceBergen/Cencora, Cardinal Health, and Morris & Dickson Co., LLC) by May 15, 2026. The MMCAP contract emphasizes price competitiveness (weighted 75 percent in evaluation) and requires vendors to maintain relationships with at least two of the three authorized wholesalers with chargeback systems in place. Neither solicitation identifies explicit set-aside designations for disadvantaged enterprises.